Global Psoriasis Drug Market
Global Psoriasis Drug Market

Psoriasis Drug Comprehensive Study by Type (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Wholesalers, Distributors, Retailers), End User (Hospital, Drugs Store) Players and Region - Global Market Outlook to 2024

Psoriasis Drug Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 219 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Psoriasis drug is used for diagnosis of Psoriasis disease and it is a common disorder of the skin, immune system, and joints that are influenced by genetic and environmental factors. It is used for the diagnosis of psoriasis by using topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients. Psoriasis Drugs can induce psoriasis de novo or induce lesions in previously unaffected skin and can exacerbate psoriasis in a patient already afflicted with psoriasis by treatment resistance or causing flares.

The market study is being classified by Type (Biologic Drugs, Small Molecule Systemic Drugs and Tropical Therapies) and major geographies with country level break-up.

AbbVie (United States), Johnson & Johnson (United States), Bayer AG (Germany), Galderma S.A.(Switzerland), Bristol-Myers Squibb (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Merz Pharma GmbH & Co. KGaA (Germany), Bausch Health Companies Inc. (Canada), LEO Pharma A/S (Denmark) and GlaxoSmithKline plc (United kingdom) are some of the key players profiled in the study.

The Players having a strong hold in the market are AbbVie, Johnson & Johnson, Bayer AG, and Galderma S.A.. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Psoriasis Drug market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Psoriasis Drug market by Type, Application and Region.

On the basis of geography, the market of Psoriasis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Disease Burden and Demand for Psoriasis Drugs in Emerging Economies
  • Rising use of Combination Therapies Globally

Market Trend
  • The growing use of Interleukin Inhibitors

Restraints
  • Strict Government Regulations and FDA Regulations

Opportunities
  • Increase in Psoriasis Research and Pipeline Drugs





Key Target Audience
Psoriasis Drug Manufacturers, Psoriasis Drug Suppliers, Wholesalers, Distributors, and Retailers of Psoriasis Drug, Healthcare Industry, Research Organization and Governmental Bodies

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Biologic Drugs
  • Small Molecule Systemic Drugs
  • Tropical Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Topical

By Distribution Channel
  • Wholesalers
  • Distributors
  • Retailers

By End User
  • Hospital
  • Drugs Store

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Disease Burden and Demand for Psoriasis Drugs in Emerging Economies
      • 3.2.2. Rising use of Combination Therapies Globally
    • 3.3. Market Trends
      • 3.3.1. The growing use of Interleukin Inhibitors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Psoriasis Drug, by Type, Route of Administration, Distribution Channel, End User and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Psoriasis Drug (Value)
      • 5.2.1. Global Psoriasis Drug by: Type (Value)
        • 5.2.1.1. Biologic Drugs
        • 5.2.1.2. Small Molecule Systemic Drugs
        • 5.2.1.3. Tropical Therapies
      • 5.2.2. Global Psoriasis Drug by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Topical
      • 5.2.3. Global Psoriasis Drug by: Distribution Channel (Value)
        • 5.2.3.1. Wholesalers
        • 5.2.3.2. Distributors
        • 5.2.3.3. Retailers
      • 5.2.4. Global Psoriasis Drug by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Drugs Store
      • 5.2.5. Global Psoriasis Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Psoriasis Drug (Volume)
      • 5.3.1. Global Psoriasis Drug by: Type (Volume)
        • 5.3.1.1. Biologic Drugs
        • 5.3.1.2. Small Molecule Systemic Drugs
        • 5.3.1.3. Tropical Therapies
      • 5.3.2. Global Psoriasis Drug by: Route of Administration (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Parenteral
        • 5.3.2.3. Topical
      • 5.3.3. Global Psoriasis Drug by: Distribution Channel (Volume)
        • 5.3.3.1. Wholesalers
        • 5.3.3.2. Distributors
        • 5.3.3.3. Retailers
      • 5.3.4. Global Psoriasis Drug by: End User (Volume)
        • 5.3.4.1. Hospital
        • 5.3.4.2. Drugs Store
      • 5.3.5. Global Psoriasis Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Psoriasis Drug (Price)
      • 5.4.1. Global Psoriasis Drug by: Type (Price)
  • 6. Psoriasis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Galderma S.A.(Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merz Pharma GmbH & Co. KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bausch Health Companies Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. LEO Pharma A/S (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GlaxoSmithKline plc (United kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Psoriasis Drug Sale, by Type, Route of Administration, Distribution Channel, End User and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Psoriasis Drug (Value)
      • 7.2.1. Global Psoriasis Drug by: Type (Value)
        • 7.2.1.1. Biologic Drugs
        • 7.2.1.2. Small Molecule Systemic Drugs
        • 7.2.1.3. Tropical Therapies
      • 7.2.2. Global Psoriasis Drug by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Topical
      • 7.2.3. Global Psoriasis Drug by: Distribution Channel (Value)
        • 7.2.3.1. Wholesalers
        • 7.2.3.2. Distributors
        • 7.2.3.3. Retailers
      • 7.2.4. Global Psoriasis Drug by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Drugs Store
      • 7.2.5. Global Psoriasis Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Psoriasis Drug (Volume)
      • 7.3.1. Global Psoriasis Drug by: Type (Volume)
        • 7.3.1.1. Biologic Drugs
        • 7.3.1.2. Small Molecule Systemic Drugs
        • 7.3.1.3. Tropical Therapies
      • 7.3.2. Global Psoriasis Drug by: Route of Administration (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Parenteral
        • 7.3.2.3. Topical
      • 7.3.3. Global Psoriasis Drug by: Distribution Channel (Volume)
        • 7.3.3.1. Wholesalers
        • 7.3.3.2. Distributors
        • 7.3.3.3. Retailers
      • 7.3.4. Global Psoriasis Drug by: End User (Volume)
        • 7.3.4.1. Hospital
        • 7.3.4.2. Drugs Store
      • 7.3.5. Global Psoriasis Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Psoriasis Drug (Price)
      • 7.4.1. Global Psoriasis Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Psoriasis Drug: by Type(USD Million)
  • Table 2. Psoriasis Drug Biologic Drugs , by Region USD Million (2013-2018)
  • Table 3. Psoriasis Drug Small Molecule Systemic Drugs , by Region USD Million (2013-2018)
  • Table 4. Psoriasis Drug Tropical Therapies , by Region USD Million (2013-2018)
  • Table 5. Psoriasis Drug: by Route of Administration(USD Million)
  • Table 6. Psoriasis Drug Oral , by Region USD Million (2013-2018)
  • Table 7. Psoriasis Drug Parenteral , by Region USD Million (2013-2018)
  • Table 8. Psoriasis Drug Topical , by Region USD Million (2013-2018)
  • Table 9. Psoriasis Drug: by Distribution Channel(USD Million)
  • Table 10. Psoriasis Drug Wholesalers , by Region USD Million (2013-2018)
  • Table 11. Psoriasis Drug Distributors , by Region USD Million (2013-2018)
  • Table 12. Psoriasis Drug Retailers , by Region USD Million (2013-2018)
  • Table 13. Psoriasis Drug: by End User(USD Million)
  • Table 14. Psoriasis Drug Hospital , by Region USD Million (2013-2018)
  • Table 15. Psoriasis Drug Drugs Store , by Region USD Million (2013-2018)
  • Table 16. South America Psoriasis Drug, by Country USD Million (2013-2018)
  • Table 17. South America Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 18. South America Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 19. South America Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 20. South America Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 21. Brazil Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 22. Brazil Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 23. Brazil Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 24. Brazil Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 25. Argentina Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 26. Argentina Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 27. Argentina Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 28. Argentina Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 29. Rest of South America Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 30. Rest of South America Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 31. Rest of South America Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 32. Rest of South America Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 33. Asia Pacific Psoriasis Drug, by Country USD Million (2013-2018)
  • Table 34. Asia Pacific Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 35. Asia Pacific Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 36. Asia Pacific Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 37. Asia Pacific Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 38. China Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 39. China Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 40. China Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 41. China Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 42. Japan Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 43. Japan Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 44. Japan Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 45. Japan Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 46. India Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 47. India Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 48. India Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 49. India Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 50. South Korea Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 51. South Korea Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 52. South Korea Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 53. South Korea Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 54. Taiwan Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 55. Taiwan Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 56. Taiwan Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 57. Taiwan Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 58. Australia Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 59. Australia Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 60. Australia Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 61. Australia Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 62. Rest of Asia-Pacific Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 63. Rest of Asia-Pacific Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 66. Europe Psoriasis Drug, by Country USD Million (2013-2018)
  • Table 67. Europe Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 68. Europe Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 69. Europe Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 70. Europe Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 71. Germany Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 72. Germany Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 73. Germany Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 74. Germany Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 75. France Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 76. France Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 77. France Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 78. France Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 79. Italy Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 80. Italy Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 81. Italy Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 82. Italy Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 83. United Kingdom Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 84. United Kingdom Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 85. United Kingdom Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 86. United Kingdom Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 87. Netherlands Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 88. Netherlands Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 89. Netherlands Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 90. Netherlands Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 91. Rest of Europe Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 92. Rest of Europe Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 93. Rest of Europe Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 94. Rest of Europe Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 95. MEA Psoriasis Drug, by Country USD Million (2013-2018)
  • Table 96. MEA Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 97. MEA Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 98. MEA Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 99. MEA Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 100. Middle East Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 101. Middle East Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 102. Middle East Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 103. Middle East Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 104. Africa Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 105. Africa Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 106. Africa Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 107. Africa Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 108. North America Psoriasis Drug, by Country USD Million (2013-2018)
  • Table 109. North America Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 110. North America Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 111. North America Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 112. North America Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 113. United States Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 114. United States Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 115. United States Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 116. United States Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 117. Canada Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 118. Canada Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 119. Canada Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 120. Canada Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 121. Mexico Psoriasis Drug, by Type USD Million (2013-2018)
  • Table 122. Mexico Psoriasis Drug, by Route of Administration USD Million (2013-2018)
  • Table 123. Mexico Psoriasis Drug, by Distribution Channel USD Million (2013-2018)
  • Table 124. Mexico Psoriasis Drug, by End User USD Million (2013-2018)
  • Table 125. Psoriasis Drug Sales: by Type(K Units)
  • Table 126. Psoriasis Drug Sales Biologic Drugs , by Region K Units (2013-2018)
  • Table 127. Psoriasis Drug Sales Small Molecule Systemic Drugs , by Region K Units (2013-2018)
  • Table 128. Psoriasis Drug Sales Tropical Therapies , by Region K Units (2013-2018)
  • Table 129. Psoriasis Drug Sales: by Route of Administration(K Units)
  • Table 130. Psoriasis Drug Sales Oral , by Region K Units (2013-2018)
  • Table 131. Psoriasis Drug Sales Parenteral , by Region K Units (2013-2018)
  • Table 132. Psoriasis Drug Sales Topical , by Region K Units (2013-2018)
  • Table 133. Psoriasis Drug Sales: by Distribution Channel(K Units)
  • Table 134. Psoriasis Drug Sales Wholesalers , by Region K Units (2013-2018)
  • Table 135. Psoriasis Drug Sales Distributors , by Region K Units (2013-2018)
  • Table 136. Psoriasis Drug Sales Retailers , by Region K Units (2013-2018)
  • Table 137. Psoriasis Drug Sales: by End User(K Units)
  • Table 138. Psoriasis Drug Sales Hospital , by Region K Units (2013-2018)
  • Table 139. Psoriasis Drug Sales Drugs Store , by Region K Units (2013-2018)
  • Table 140. South America Psoriasis Drug Sales, by Country K Units (2013-2018)
  • Table 141. South America Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 142. South America Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 143. South America Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 144. South America Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 145. Brazil Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 146. Brazil Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 147. Brazil Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 148. Brazil Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 149. Argentina Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 150. Argentina Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 151. Argentina Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 152. Argentina Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 153. Rest of South America Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 154. Rest of South America Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 155. Rest of South America Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 156. Rest of South America Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 157. Asia Pacific Psoriasis Drug Sales, by Country K Units (2013-2018)
  • Table 158. Asia Pacific Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 159. Asia Pacific Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 160. Asia Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 161. Asia Pacific Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 162. China Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 163. China Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 164. China Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 165. China Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 166. Japan Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 167. Japan Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 168. Japan Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 169. Japan Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 170. India Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 171. India Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 172. India Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 173. India Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 174. South Korea Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 175. South Korea Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 176. South Korea Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 177. South Korea Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 178. Taiwan Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 179. Taiwan Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 180. Taiwan Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 181. Taiwan Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 182. Australia Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 183. Australia Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 184. Australia Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 185. Australia Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 186. Rest of Asia-Pacific Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 187. Rest of Asia-Pacific Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 188. Rest of Asia-Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 189. Rest of Asia-Pacific Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 190. Europe Psoriasis Drug Sales, by Country K Units (2013-2018)
  • Table 191. Europe Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 192. Europe Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 193. Europe Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 194. Europe Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 195. Germany Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 196. Germany Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 197. Germany Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 198. Germany Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 199. France Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 200. France Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 201. France Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 202. France Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 203. Italy Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 204. Italy Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 205. Italy Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 206. Italy Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 207. United Kingdom Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 208. United Kingdom Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 209. United Kingdom Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 210. United Kingdom Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 211. Netherlands Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 212. Netherlands Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 213. Netherlands Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 214. Netherlands Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 215. Rest of Europe Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 216. Rest of Europe Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 217. Rest of Europe Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 218. Rest of Europe Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 219. MEA Psoriasis Drug Sales, by Country K Units (2013-2018)
  • Table 220. MEA Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 221. MEA Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 222. MEA Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 223. MEA Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 224. Middle East Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 225. Middle East Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 226. Middle East Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 227. Middle East Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 228. Africa Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 229. Africa Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 230. Africa Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 231. Africa Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 232. North America Psoriasis Drug Sales, by Country K Units (2013-2018)
  • Table 233. North America Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 234. North America Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 235. North America Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 236. North America Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 237. United States Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 238. United States Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 239. United States Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 240. United States Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 241. Canada Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 242. Canada Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 243. Canada Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 244. Canada Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 245. Mexico Psoriasis Drug Sales, by Type K Units (2013-2018)
  • Table 246. Mexico Psoriasis Drug Sales, by Route of Administration K Units (2013-2018)
  • Table 247. Mexico Psoriasis Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 248. Mexico Psoriasis Drug Sales, by End User K Units (2013-2018)
  • Table 249. Psoriasis Drug: by Type(USD/Units)
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Psoriasis Drug: by Type(USD Million)
  • Table 262. Psoriasis Drug Biologic Drugs , by Region USD Million (2019-2024)
  • Table 263. Psoriasis Drug Small Molecule Systemic Drugs , by Region USD Million (2019-2024)
  • Table 264. Psoriasis Drug Tropical Therapies , by Region USD Million (2019-2024)
  • Table 265. Psoriasis Drug: by Route of Administration(USD Million)
  • Table 266. Psoriasis Drug Oral , by Region USD Million (2019-2024)
  • Table 267. Psoriasis Drug Parenteral , by Region USD Million (2019-2024)
  • Table 268. Psoriasis Drug Topical , by Region USD Million (2019-2024)
  • Table 269. Psoriasis Drug: by Distribution Channel(USD Million)
  • Table 270. Psoriasis Drug Wholesalers , by Region USD Million (2019-2024)
  • Table 271. Psoriasis Drug Distributors , by Region USD Million (2019-2024)
  • Table 272. Psoriasis Drug Retailers , by Region USD Million (2019-2024)
  • Table 273. Psoriasis Drug: by End User(USD Million)
  • Table 274. Psoriasis Drug Hospital , by Region USD Million (2019-2024)
  • Table 275. Psoriasis Drug Drugs Store , by Region USD Million (2019-2024)
  • Table 276. South America Psoriasis Drug, by Country USD Million (2019-2024)
  • Table 277. South America Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 278. South America Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 279. South America Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 280. South America Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 281. Brazil Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 282. Brazil Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 283. Brazil Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 284. Brazil Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 285. Argentina Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 286. Argentina Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 287. Argentina Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 288. Argentina Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 289. Rest of South America Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 290. Rest of South America Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 291. Rest of South America Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 292. Rest of South America Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 293. Asia Pacific Psoriasis Drug, by Country USD Million (2019-2024)
  • Table 294. Asia Pacific Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 295. Asia Pacific Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 296. Asia Pacific Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 297. Asia Pacific Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 298. China Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 299. China Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 300. China Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 301. China Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 302. Japan Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 303. Japan Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 304. Japan Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 305. Japan Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 306. India Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 307. India Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 308. India Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 309. India Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 310. South Korea Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 311. South Korea Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 312. South Korea Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 313. South Korea Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 314. Taiwan Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 315. Taiwan Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 316. Taiwan Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 317. Taiwan Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 318. Australia Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 319. Australia Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 320. Australia Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 321. Australia Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 322. Rest of Asia-Pacific Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 323. Rest of Asia-Pacific Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 324. Rest of Asia-Pacific Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 325. Rest of Asia-Pacific Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 326. Europe Psoriasis Drug, by Country USD Million (2019-2024)
  • Table 327. Europe Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 328. Europe Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 329. Europe Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 330. Europe Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 331. Germany Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 332. Germany Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 333. Germany Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 334. Germany Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 335. France Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 336. France Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 337. France Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 338. France Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 339. Italy Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 340. Italy Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 341. Italy Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 342. Italy Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 343. United Kingdom Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 344. United Kingdom Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 345. United Kingdom Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 346. United Kingdom Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 347. Netherlands Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 348. Netherlands Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 349. Netherlands Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 350. Netherlands Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 351. Rest of Europe Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 352. Rest of Europe Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 353. Rest of Europe Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 354. Rest of Europe Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 355. MEA Psoriasis Drug, by Country USD Million (2019-2024)
  • Table 356. MEA Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 357. MEA Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 358. MEA Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 359. MEA Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 360. Middle East Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 361. Middle East Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 362. Middle East Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 363. Middle East Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 364. Africa Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 365. Africa Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 366. Africa Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 367. Africa Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 368. North America Psoriasis Drug, by Country USD Million (2019-2024)
  • Table 369. North America Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 370. North America Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 371. North America Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 372. North America Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 373. United States Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 374. United States Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 375. United States Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 376. United States Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 377. Canada Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 378. Canada Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 379. Canada Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 380. Canada Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 381. Mexico Psoriasis Drug, by Type USD Million (2019-2024)
  • Table 382. Mexico Psoriasis Drug, by Route of Administration USD Million (2019-2024)
  • Table 383. Mexico Psoriasis Drug, by Distribution Channel USD Million (2019-2024)
  • Table 384. Mexico Psoriasis Drug, by End User USD Million (2019-2024)
  • Table 385. Psoriasis Drug Sales: by Type(K Units)
  • Table 386. Psoriasis Drug Sales Biologic Drugs , by Region K Units (2019-2024)
  • Table 387. Psoriasis Drug Sales Small Molecule Systemic Drugs , by Region K Units (2019-2024)
  • Table 388. Psoriasis Drug Sales Tropical Therapies , by Region K Units (2019-2024)
  • Table 389. Psoriasis Drug Sales: by Route of Administration(K Units)
  • Table 390. Psoriasis Drug Sales Oral , by Region K Units (2019-2024)
  • Table 391. Psoriasis Drug Sales Parenteral , by Region K Units (2019-2024)
  • Table 392. Psoriasis Drug Sales Topical , by Region K Units (2019-2024)
  • Table 393. Psoriasis Drug Sales: by Distribution Channel(K Units)
  • Table 394. Psoriasis Drug Sales Wholesalers , by Region K Units (2019-2024)
  • Table 395. Psoriasis Drug Sales Distributors , by Region K Units (2019-2024)
  • Table 396. Psoriasis Drug Sales Retailers , by Region K Units (2019-2024)
  • Table 397. Psoriasis Drug Sales: by End User(K Units)
  • Table 398. Psoriasis Drug Sales Hospital , by Region K Units (2019-2024)
  • Table 399. Psoriasis Drug Sales Drugs Store , by Region K Units (2019-2024)
  • Table 400. South America Psoriasis Drug Sales, by Country K Units (2019-2024)
  • Table 401. South America Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 402. South America Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 403. South America Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 404. South America Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 405. Brazil Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 406. Brazil Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 407. Brazil Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 408. Brazil Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 409. Argentina Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 410. Argentina Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 411. Argentina Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 412. Argentina Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 413. Rest of South America Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 414. Rest of South America Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 415. Rest of South America Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 416. Rest of South America Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 417. Asia Pacific Psoriasis Drug Sales, by Country K Units (2019-2024)
  • Table 418. Asia Pacific Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 419. Asia Pacific Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 420. Asia Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 421. Asia Pacific Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 422. China Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 423. China Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 424. China Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 425. China Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 426. Japan Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 427. Japan Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 428. Japan Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 429. Japan Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 430. India Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 431. India Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 432. India Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 433. India Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 434. South Korea Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 435. South Korea Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 436. South Korea Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 437. South Korea Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 438. Taiwan Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 439. Taiwan Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 440. Taiwan Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 441. Taiwan Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 442. Australia Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 443. Australia Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 444. Australia Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 445. Australia Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 446. Rest of Asia-Pacific Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 447. Rest of Asia-Pacific Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 448. Rest of Asia-Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 449. Rest of Asia-Pacific Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 450. Europe Psoriasis Drug Sales, by Country K Units (2019-2024)
  • Table 451. Europe Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 452. Europe Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 453. Europe Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 454. Europe Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 455. Germany Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 456. Germany Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 457. Germany Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 458. Germany Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 459. France Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 460. France Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 461. France Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 462. France Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 463. Italy Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 464. Italy Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 465. Italy Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 466. Italy Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 467. United Kingdom Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 468. United Kingdom Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 469. United Kingdom Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 470. United Kingdom Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 471. Netherlands Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 472. Netherlands Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 473. Netherlands Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 474. Netherlands Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 475. Rest of Europe Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 476. Rest of Europe Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 477. Rest of Europe Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 478. Rest of Europe Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 479. MEA Psoriasis Drug Sales, by Country K Units (2019-2024)
  • Table 480. MEA Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 481. MEA Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 482. MEA Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 483. MEA Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 484. Middle East Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 485. Middle East Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 486. Middle East Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 487. Middle East Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 488. Africa Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 489. Africa Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 490. Africa Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 491. Africa Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 492. North America Psoriasis Drug Sales, by Country K Units (2019-2024)
  • Table 493. North America Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 494. North America Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 495. North America Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 496. North America Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 497. United States Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 498. United States Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 499. United States Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 500. United States Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 501. Canada Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 502. Canada Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 503. Canada Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 504. Canada Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 505. Mexico Psoriasis Drug Sales, by Type K Units (2019-2024)
  • Table 506. Mexico Psoriasis Drug Sales, by Route of Administration K Units (2019-2024)
  • Table 507. Mexico Psoriasis Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 508. Mexico Psoriasis Drug Sales, by End User K Units (2019-2024)
  • Table 509. Psoriasis Drug: by Type(USD/Units)
  • Table 510. Research Programs/Design for This Report
  • Table 511. Key Data Information from Secondary Sources
  • Table 512. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Psoriasis Drug: by Type USD Million (2013-2018)
  • Figure 5. Global Psoriasis Drug: by Route of Administration USD Million (2013-2018)
  • Figure 6. Global Psoriasis Drug: by Distribution Channel USD Million (2013-2018)
  • Figure 7. Global Psoriasis Drug: by End User USD Million (2013-2018)
  • Figure 8. South America Psoriasis Drug Share (%), by Country
  • Figure 9. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 10. Europe Psoriasis Drug Share (%), by Country
  • Figure 11. MEA Psoriasis Drug Share (%), by Country
  • Figure 12. North America Psoriasis Drug Share (%), by Country
  • Figure 13. Global Psoriasis Drug: by Type K Units (2013-2018)
  • Figure 14. Global Psoriasis Drug: by Route of Administration K Units (2013-2018)
  • Figure 15. Global Psoriasis Drug: by Distribution Channel K Units (2013-2018)
  • Figure 16. Global Psoriasis Drug: by End User K Units (2013-2018)
  • Figure 17. South America Psoriasis Drug Share (%), by Country
  • Figure 18. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 19. Europe Psoriasis Drug Share (%), by Country
  • Figure 20. MEA Psoriasis Drug Share (%), by Country
  • Figure 21. North America Psoriasis Drug Share (%), by Country
  • Figure 22. Global Psoriasis Drug: by Type USD/Units (2013-2018)
  • Figure 23. Global Psoriasis Drug share by Players 2018 (%)
  • Figure 24. Global Psoriasis Drug share by Players (Top 3) 2018(%)
  • Figure 25. Global Psoriasis Drug share by Players (Top 5) 2018(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie (United States) Revenue: by Geography 2018
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 31. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 33. Galderma S.A.(Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Galderma S.A.(Switzerland) Revenue: by Geography 2018
  • Figure 35. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bristol-Myers Squibb (United States) Revenue: by Geography 2018
  • Figure 37. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis International AG (Switzerland) Revenue: by Geography 2018
  • Figure 39. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 41. Merz Pharma GmbH & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Merz Pharma GmbH & Co. KGaA (Germany) Revenue: by Geography 2018
  • Figure 43. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 44. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2018
  • Figure 45. LEO Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 46. LEO Pharma A/S (Denmark) Revenue: by Geography 2018
  • Figure 47. GlaxoSmithKline plc (United kingdom) Revenue, Net Income and Gross profit
  • Figure 48. GlaxoSmithKline plc (United kingdom) Revenue: by Geography 2018
  • Figure 49. Global Psoriasis Drug: by Type USD Million (2019-2024)
  • Figure 50. Global Psoriasis Drug: by Route of Administration USD Million (2019-2024)
  • Figure 51. Global Psoriasis Drug: by Distribution Channel USD Million (2019-2024)
  • Figure 52. Global Psoriasis Drug: by End User USD Million (2019-2024)
  • Figure 53. South America Psoriasis Drug Share (%), by Country
  • Figure 54. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 55. Europe Psoriasis Drug Share (%), by Country
  • Figure 56. MEA Psoriasis Drug Share (%), by Country
  • Figure 57. North America Psoriasis Drug Share (%), by Country
  • Figure 58. Global Psoriasis Drug: by Type K Units (2019-2024)
  • Figure 59. Global Psoriasis Drug: by Route of Administration K Units (2019-2024)
  • Figure 60. Global Psoriasis Drug: by Distribution Channel K Units (2019-2024)
  • Figure 61. Global Psoriasis Drug: by End User K Units (2019-2024)
  • Figure 62. South America Psoriasis Drug Share (%), by Country
  • Figure 63. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 64. Europe Psoriasis Drug Share (%), by Country
  • Figure 65. MEA Psoriasis Drug Share (%), by Country
  • Figure 66. North America Psoriasis Drug Share (%), by Country
  • Figure 67. Global Psoriasis Drug: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • AbbVie (United States)
  • Johnson & Johnson (United States)
  • Bayer AG (Germany)
  • Galderma S.A.(Switzerland)
  • Bristol-Myers Squibb (United States)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (United States)
  • Merz Pharma GmbH & Co. KGaA (Germany)
  • Bausch Health Companies Inc. (Canada)
  • LEO Pharma A/S (Denmark)
  • GlaxoSmithKline plc (United kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation